Article Text

Download PDFPDF
Physicochemical and biological stability of diluted vedolizumab in intravenous infusion bags
  1. Tine C J Hendrickx1,
  2. Kevin D H Balcaen2,
  3. Marielle Baert1,
  4. Jurgen Haustraete2,
  5. Bart N Lambrecht3,4
  1. 1Pharmacy, AZ Sint-Lucas, Ghent, Belgium
  2. 2Protein Core, VIB-UGent Center for Inflammation Research, Ghent, Belgium
  3. 3Laboratory for Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium
  4. 4Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium
  1. Correspondence to Tine C J Hendrickx, Pharmacy, AZ Sint-Lucas, Ghent, Belgium; tine.hendrickx{at}azstlucas.be

Abstract

Introduction Intravenous vedolizumab is a widely used monoclonal antibody for outpatients with inflammatory bowel disease. Drug preparation is performed on the day of administration, but is time consuming, causing unnecessary in-hospital patient delay and inefficient logistics for preparation and distribution. Storage of vedolizumab ready-to-administer infusions and distribution via pneumatic air tubes could streamline logistics in the outpatient setting. The aim of this study was to test the shelf life and stability of ready-to-administer intravenous infusion bags containing vedolizumab.

Methods For assessing in-use shelf life, the reconstituted product (300 mg fixed dose) was diluted to a concentration of 1.2 mg/mL in 0.9% NaCl under aseptic conditions, and stored in polyolefin infusion bags at 2–8°C prior to analysis. On replicate samples, we measured concentration, physical and chemical stability using sodium dodecyl sulphate polyacrylamide gel electrophoresis, size exclusion chromatography, and multi-angle laser light scattering, as well as biological activity using a biolayer interferometry assay to study target engagement, and endotoxin content to assess microbiological stability. Stability of ready-to-use vedolizumab was assessed also after transportation via pneumatic tube system. Samples were taken at different time points over an observation period of 30 days on four replicate samples.

Results For all parameters assessed, the ready-to-use solution of vedolizumab remained stable over a period of at least 30 days. There were no signs of protein aggregation, chemical instability, or loss of binding of the antibody to the α4β7 integrin target. There was no increase in endotoxin concentration over time. No significant difference was seen in antibody structural stability and protein aggregation between samples before and after transportation via pneumatic tube system.

Conclusion When prepared under aseptic conditions, dissolved ready-to-administer vedolizumab infusion bags can be stored long term at 2–8°C and transported via pneumatic air tube, without observable loss of antibody stability or binding activity.

  • Drug Administration Routes
  • Drug Compounding
  • Inflammatory Bowel Diseases
  • BIOTECHNOLOGY
  • Chemistry, Pharmaceutical

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text